Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models
- PMID: 30260411
- PMCID: PMC6324059
- DOI: 10.1093/nar/gky872
Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models
Abstract
In vitro cancer cell cultures are facile experimental models used widely for research and drug development. Many cancer cell lines are available and efforts are ongoing to derive new models representing the histopathological and molecular diversity of tumours. Cell models have been generated by multiple laboratories over decades and consequently their annotation is incomplete and inconsistent. Furthermore, the relationships between many patient-matched and derivative cell lines have been lost, and accessing information and datasets is time-consuming and difficult. Here, we describe the Cell Model Passports database; cellmodelpassports.sanger.ac.uk, which provides details of cell model relationships, patient and clinical information, as well as access to associated genetic and functional datasets. The Passports database currently contains curated details and standardized annotation for >1200 cell models, including cancer organoid cultures. The Passports will be updated with newly derived cell models and datasets as they are generated. Users can navigate the database via tissue, cancer-type, genetic feature and data availability to select a model most suitable for specific applications. A flexible REST-API provides programmatic data access and exploration. The Cell Model Passports are a valuable tool enabling access to high-dimensional genomic and phenotypic cancer cell model datasets empowering diverse research applications.
Figures
Similar articles
-
Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets.Nucleic Acids Res. 2021 Jan 8;49(D1):D1365-D1372. doi: 10.1093/nar/gkaa882. Nucleic Acids Res. 2021. PMID: 33068406 Free PMC article.
-
CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.Nucleic Acids Res. 2021 Jan 8;49(D1):D1083-D1093. doi: 10.1093/nar/gkaa968. Nucleic Acids Res. 2021. PMID: 33196823 Free PMC article.
-
Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.J Clin Endocrinol Metab. 2021 Apr 23;106(5):1410-1426. doi: 10.1210/clinem/dgab020. J Clin Endocrinol Metab. 2021. PMID: 33524147
-
Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer.Biochem Soc Trans. 2019 Feb 28;47(1):109-117. doi: 10.1042/BST20180375. Epub 2019 Jan 9. Biochem Soc Trans. 2019. PMID: 30626705 Review.
-
Xenograft and organoid model systems in cancer research.EMBO J. 2019 Aug 1;38(15):e101654. doi: 10.15252/embj.2019101654. Epub 2019 Jul 8. EMBO J. 2019. PMID: 31282586 Free PMC article. Review.
Cited by
-
A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.Cell Rep Med. 2024 Aug 20;5(8):101687. doi: 10.1016/j.xcrm.2024.101687. Cell Rep Med. 2024. PMID: 39168097 Free PMC article.
-
Using DeepSignalingFlow to mine signaling flows interpreting mechanism of synergy of cocktails.NPJ Syst Biol Appl. 2024 Aug 21;10(1):92. doi: 10.1038/s41540-024-00421-w. NPJ Syst Biol Appl. 2024. PMID: 39169016 Free PMC article.
-
Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies.Inorg Chem. 2024 Aug 12;63(32):14958-14968. doi: 10.1021/acs.inorgchem.4c01586. Epub 2024 Jul 31. Inorg Chem. 2024. PMID: 39083592 Free PMC article.
-
SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia.Br J Biomed Sci. 2023 Feb 21;80:11041. doi: 10.3389/bjbs.2023.11041. eCollection 2023. Br J Biomed Sci. 2023. PMID: 36895328 Free PMC article.
-
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.Cancer Med. 2023 May;12(9):10267-10279. doi: 10.1002/cam4.5756. Epub 2023 Mar 27. Cancer Med. 2023. PMID: 36971051 Free PMC article.
References
-
- Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G. et al. . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350:2129–2139. - PubMed
-
- Shaw A.T., Kim D.-W., Nakagawa K., Seto T., Crinó L., Ahn M.-J., De Pas T., Besse B., Solomon B.J., Blackhall F. et al. . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013; 368:2385–2394. - PubMed
-
- Brown R.W., Henderson J.H.. The mass production and distribution of HeLa cells at Tuskegee Institute, 1953-55. J. Hist. Med. Allied Sci. 1983; 38:415–431. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
